Researchers Identified New Driver of Breast Cancer Resistance
A specific enzyme may help cancer cells survive treatment, potentially opening new paths for future therapy.
Updated on Sept. 30, 2026 in Cancer
Live Poll
Does the discovery of new cancer resistance mechanisms give you more hope for future treatments?
Researchers at Boston Children's Hospital have identified the enzyme FAH as a key driver of treatment resistance in patients with hormone receptor-positive breast cancer. This finding explains how some cancer cells regrow after therapy with CDK4/6 inhibitors.
Why it matters
Patients treated with CDK4/6 inhibitors often face cancer recurrence due to therapy resistance, a major hurdle in long-term management. Understanding this metabolic pathway could eventually allow clinicians to better predict or prevent treatment failure.
In a preclinical study published in Science Advances, researchers found that the enzyme FAH enters the nucleus of breast cancer cells following CDK4/6 inhibitor treatment. This study highlights the molecular interaction between FAH and CDK9 that facilitates cellular resistance.
The players
Boston Children's Hospital
A pediatric research and teaching hospital that conducts extensive studies into the molecular mechanisms of disease.
The details
When cancer cells are exposed to CDK4/6 inhibitors, the enzyme FAH translocates into the cell nucleus. Once inside, FAH stimulates the activity of CDK9, a regulator that promotes cell survival and growth. By boosting this pathway, the enzyme helps the cancer cells persist despite the presence of standard inhibitor therapies.
Timeline
September 30, 2026: Research findings were published in Science Advances.
Health Landscape
CDK4/6 inhibitors represent a standard treatment modality for hormone receptor-positive breast cancer, yet resistance remains a significant clinical limitation. This research identifies a novel metabolic mechanism that directly challenges the durability of current treatment protocols.
This study identifies a biological pathway that may explain why some patients experience cancer recurrence during standard therapy. If you are undergoing breast cancer treatment, any concerns about response or resistance are important topics to discuss with your oncology team.
The takeaway
The discovery of nuclear FAH suggests that blocking specific enzymes might eventually help overcome treatment resistance. Patients should focus on maintaining open communication with their oncologists regarding the effectiveness of their current treatment plan.
Further reading
For broader context on how medical research identifies new ways to fight tumor growth, visit Cancer.
Live Poll
Does the discovery of new cancer resistance mechanisms give you more hope for future treatments?
